Fuad El-Hibri Organization Blog

Fuad El-Hibri Online

Entries Tagged ‘Emergent BioSolutions’

Nominations Being Accepted Now for 2010 El-Hibri Peace Education Prize

The El-Hibri Peace Education Prize is awarded yearly to an individual who is making valuable contributions to peace education and social justice in the Middle East.  The purpose of the $10,000 prize is to recognize outstanding peace educators, to provide financial support to continue peace education and study, and to promote the importance of peace [...]

500 Most Influential Muslims: Science and Technology

The Prince Alwaleed Bin Talaal Center for Muslim-Christian Understanding and The Royal Islamic Strategic Studies Centre published its first edition in what promises to be an annual series of insight into the movers and shakers of the Muslim world. Entitled The 500 Most Influential Muslims 2009, the book categorizes Muslims’ influential capacities into 15 [...]

Fuad el-Hibri, king of anthrax, wins an award from Ernst & Young

Marie-José Daoud
Awarded the Ernst and Young prize for Entrepreneur of the year 2009 in the Technology category for the Greater Washington region last June, Fuad El-Hibri is the CEO of Emergent Biosolutions, an American company that supplies the anthrax vaccine to the American government. He is in line for the national E&Y 2009 prize, which [...]

Emergent BioSolutions reacts to BARDA’s Request for Proposal cancellation

by Nick Rees on December 8, 2009
Fuad El-Hibri
The Office of the Biomedical Advanced Research and Development Authority has advised Emergent BioSolutions that while BARDA’s Request for Proposal has been canceled, Emergent is encouraged to submit a proposal for the office’s Broad Agency Announcement.
BARDA canceled the RFP for the procurement for rPA vaccines after [...]

Emergent BioSolutions Inc. (EBS) CEO & Chairman, 10% Owner Fuad El-hibri sells 15,000 Shares

CEO & Chairman, 10% Owner of Emergent BioSolutions Inc. (EBS) Fuad El-hibri sells 15,000 shares of EBS on 08/11/2009 at an average price of $16.78 a share.
EMERGENT BIOSULUTIONS INC. is a leading biopharmaceutical company dedicated to one simple mission – to protect life. EBS develops manufactures and commercializes vaccines and therapeutics that assist the body\’s [...]

Emergent BioSolutions hands out bonuses

Washington Business Journal reports
Emergent BioSolutions hands out bonuses
Bonus may be a bad word right now — but not for a biotech that is actually making money.
Alongside minimal pay raises, Emergent BioSolutions Inc. execs received bonuses in 2008 that increased anywhere from 5 percent to 43 percent from their 2007 bonuses. Fuad El-Hibri, chief executive officer [...]

Maker of anthrax vaccine discusses challenges of marketing overseas

BioPort is the only FDA-licensed producer of the anthrax vaccine.

Fuad El-Hibri, chairman and CEO of Emergent BioSolutions Inc., speaks March 9 in Sage Hall. Kevin Stearns/University Photography

On March 9, MBA students taking International Political Risk Management, a course taught by Elena Iankova, a lecturer at the S.C. Johnson Graduate School of [...]

EMERGENT BIOSOLUTIONS ANNOUNCES MANAGEMENT CHANGES

ROCKVILLE, MD, May 16, 2007—Emergent BioSolutions Inc. (NYSE: EBS) announced today the consolidation of the president and chief operating officer position.  With this change, Daniel J. Abdun-Nabi, the company’s president, will also take on the role of chief operating officer. In this combined role, Mr. Abdun-Nabi will oversee all of the company’s product development, manufacturing [...]

EMERGENT BIOSOLUTIONS ANNOUNCES THE APPOINTMENT OF DENISE LANDRY AS SENIOR VICE PRESIDENT, QUALITY

ROCKVILLE, MD, October 9, 2007—Emergent BioSolutions Inc. (NYSE: EBS) announced today that Ms. Denise Landry has joined the company as Senior Vice President, Quality with responsibility for managing and overseeing all Quality activities company-wide.  Ms. Landry has broad-based quality experience for pharmaceutical and biologics operations, including activities relating to all phases of product development, regulatory [...]

EMERGENT BIOSOLUTIONS SIGNS $448 MILLION THREE YEAR CONTRACT WITH DEPARTMENT OF HEALTH AND HUMAN SERVICES

ROCKVILLE, MD, September 26, 2007—Emergent BioSolutions Inc. (NYSE: EBS), announced today that it has signed a three year contract with the U.S. Department of Health and Human Services (HHS), with a total value of up to $448 million.  Components of the contract include:
(i)           $400 million firm fixed-price for delivery of 18.75 million doses of BioThrax® [...]